Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Operating Leases (2019 - 2025)

Myriad Genetics (MYGN) has disclosed Operating Leases for 7 consecutive years, with $83.0 million as the latest value for Q4 2025.

  • Quarterly Operating Leases fell 5.57% to $83.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $83.0 million through Dec 2025, down 5.57% year-over-year, with the annual reading at $83.0 million for FY2025, 5.57% down from the prior year.
  • Operating Leases for Q4 2025 was $83.0 million at Myriad Genetics, down from $84.9 million in the prior quarter.
  • The five-year high for Operating Leases was $130.9 million in Q4 2022, with the low at $5.9 million in Q1 2023.
  • Average Operating Leases over 5 years is $76.6 million, with a median of $85.6 million recorded in 2025.
  • The sharpest move saw Operating Leases plummeted 95.21% in 2023, then surged 1498.31% in 2024.
  • Over 5 years, Operating Leases stood at $79.3 million in 2021, then skyrocketed by 65.07% to $130.9 million in 2022, then dropped by 25.59% to $97.4 million in 2023, then decreased by 9.75% to $87.9 million in 2024, then fell by 5.57% to $83.0 million in 2025.
  • According to Business Quant data, Operating Leases over the past three periods came in at $83.0 million, $84.9 million, and $86.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.